Secondary antibody deficiency in chronic lymphocytic leukemia and non-Hodgkin lymphoma: Recommendations from an international expert panel

Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review

“…Several cut-offs for hypogammaglobulinemia are used in the literature, suggesting a potential lack of consistency across studies ( 37 – 40 ). The authors agree with the recent expert consensus review published in Blood Reviews , where mild (4–6 g/L) and severe (<4 g/L) definitions of hypogammaglobulinaemia are suggested ( 41 ).…”

“…This level of granularity in reporting rates of specific subtypes of SID and related infections might not be a priority for hematologists and hemato-oncologists with the main focus on treating the malignancy. However, we believe that collecting these data might help highlight trends and possible correlations that could inform changes in the management of HMs and related infections in everyday clinical practice, such as improving supportive care and serving as a stimulus for development of approaches that include the early testing and detection of immunodeficiency alongside prevention and treatment of infection as part of the routine management of these HMs ( 41 ). Therefore, we undertook this systematic literature review to provide insight into the cancer treatments associated with SID, including the incidence of infections, neutropenia, and hypogammaglobulinemia among patients undergoing systemic treatment for CLL, MM, and NHL.…”

“…The authors believe that, while treatment of the malignancy is clearly of primary importance, there are still several knowledge gaps on the management of SID ( Table 1 ); therefore, efforts need to be undertaken to improve awareness of how to diagnose and treat patients with hypogammaglobulinemia, CID, and infections in HMs, as well as optimize treatments to prevent recurrent and severe infections. Without increased recording and reporting of Ig levels in this patient population, the benefits of a range management strategies such as infection exposure mitigation strategies, vaccination, antibiotics, antiviral drugs, and immunoglobulin replacement therapy (IgRT) cannot be fully evaluated ( 41 ).…”

An interdisciplinary approach to the management of oncohematological patients with immunodeficiency: clinical cases. A review

“…Одной из неудовлетворенных потребностей в области диаг ностики ВИД является отсутствие четкого консенсуса в отношении того, какие уровни IgG следует использовать для однозначного определения гипогаммаглобулинемии [7]. В недавнем экспертном консенсусном обзоре концентрация IgG в сыворотке крови <4 г/л определена как тяжелая гипогаммаглобулинемия, а уровень 4-6 г/л -как легкая гипогаммаглобулинемия [15].…”

“…Предыдущее использование внутривенных (ВВИГ) или подкожных Ig (ПКИГ) может исказить результаты ответа на вакцину. Поэтому рекомендуется подождать 3-6 мес после любого введения Ig [15]. В совокупности анализ истории болезни пациента и связанных с ним факторов риска, оценка уровней IgG и реакция на вакцинацию являются ключевыми неотъемлемыми частями диагностики ВИД у пациента с гемобластозом.…”